Dr. Gail Roboz discusses the latest research, clinical trials and breakthroughs to be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting

Dr. Gail J. Roboz appeared as a guest on Fox 24’s News Talk Central to discuss the latest research, clinical trials and breakthroughs to be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. Please view the WGXA-FOX 24 segment

“One of the most important things coming out of this meeting is that there is more collaboration between people and there’s more collaboration between pharmaceutical companies to bring new drugs and new technologies together,” notes Dr. Roboz.

To follow ASCO’s annual meeting
Twitter   Facebook

To follow Cornell Leukemia
Twitter   Facebook

 


The broad spectrum of myelodysplastic syndrome

Ellen Ritchie, M.D., assistant professor of clinical medicine, joins OncLive in a discussion on the current best practices in the management of myelodysplastic syndrome and how the latest research is likely to impact the field.

“I think it’s very important when we talk to patients about MDS that we talk about the broad spectrum of disease and that we don’t label it as cancer necessarily. Because I think that it can almost be as detrimental to their quality of life with the disease afterward, by labeling it as such, than the treatments and supportive care that we have to give them.” – Dr. Ellen Ritchie

To learn more about our CRUSH!!MDS program and to participate in a clinical trial [go]

See original post on the Meyer Cancer Center site May 12, 2016


Dr. Pinkal Desai Discusses a Clinical Trial of SGI-110 for People with MDS/MPN and CMMoL

This clinical study is aimed at men and women with a diagnosis of: Chronic Neutrophilic Leukemia (CNL), Chronic Myelomonocytic Leuekmia (CMML), atypical Chronic Myeloid Leukemia (aCML), Juvenile Myelomonocytic Leukemia (JMML), and Myelodysplastic & Myeloproliferative Neoplasm Unclassifiable (MDS/MPN-U). Click here to learn more or see if you are eligible to participate.


Some Pediatric Regimens Can Be Successful in Adults With ALL

When Jody Winsick-Soluri was diagnosed with acute lymphoblastic leukemia (ALL), she found out she had a chromosomal abnormality, the Philadelphia chromosome, which made her prospects bleak.

“I was bleeding out; they said I might only have 24 hours to live,” Winsick-Soluri remembers. Now, after many rounds of chemotherapy, total body irradiation, two bone marrow transplants and seven years, Winsick Soluri takes a targeted drug — Sprycel (dasatinib) — that blocks a protein leukemia cells need to proliferate. “Now, I’m four-and-a-half years out from the last transplant,” the New Jersey mother of four says. “More people with ALL are staying alive a lot longer.”

See the original article posted on March 16, 2016


Phase 3 Trial Shows CPX-351 (Vyxeos) Boosts Overall Survival in AML

Frontline treatment with CPX-351 (Vyxeos) significantly boosted overall survival (OS) for older patients with high-risk, secondary acute myeloid leukemia (AML) when compared with the current standard of care, cytarabine and daunorubicin, according to data from a phase III trial released by the drug’s developer, Celator Pharmaceuticals, Inc.
“These findings confirm that Vyxeos provides the first opportunity we’ve had in decades to extend survival for patients with high-risk AML,” added Gail Roboz, MD, Professor of Medicine and Director of the Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York, said in a statement. “Also, more patients in remission means more who are eligible for potentially curative therapy.” To see the full article and data visit Targeted Oncology

What to Expect When You’re Expecting MDS

Dr. Ritchie provides and in-depth look at what it takes to diagnose MDS. For more information visit crushdmds.org.


Dr. Desai – Treatment for Intermediate & High Risk MDS

Dr. Desai discusses approved treatments for intermediate and high risk MDS. For more information visit crushmds.org.